Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age Wei Zhao,a,b,c,d Helen Hill,e,f Chantal Le Guellec,g Tim Neal,h Sarah Mahoney,i Stephane Paulus,i Charlotte Castellan,j Behrouz Kassai,j Johannes N. van den Anker,k,l,m,n Gregory L. Kearns,o,p Mark A. Turner,e,f Evelyne Jacqz-Aigrain,b,c,d on behalf of the TINN Consortium

Ciprofloxacin is used in neonates with suspected or documented Gram-negative serious infections. Currently, its use is off-label partly because of lack of pharmacokinetic studies. Within the FP7 EU project TINN (Treat Infection in NeoNates), our aim was to evaluate the population pharmacokinetics of ciprofloxacin in neonates and young infants